Tradestie Institutional Equity Comparison Engine
ENTX vs MTNB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (3โ0 Pillars ยท 4โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus MTNB at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ENTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro) against MTNB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ENTX N/M vs MTNB N/M Fwd P/E
Growth & Margin Winner
ENTX
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs -100.0%
Momentum & Technical Winner
ENTX
1Y +24.7% vs -1.0% ยท 52W Pos 73% vs 22%
Options & Structure Winner
ENTX
CONSOLIDATION (33rd %ile IV) vs UNCLASSIFIED (N/A IV)
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap
$571.2M
1M Return
+9.44%
1Y Return
+24.72%
Forward P/E
N/M
Unified AI Score
47.5 / 100
HOLD
Tech 52.0
Fund 49.0
Flow 72.0
Mom 50.0
MTNB
NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.80
-1.26% 1D
Market Cap
$902,069
1M Return
-53.22%
1Y Return
-1.01%
Forward P/E
N/M
Unified AI Score
52.8 / 100
HOLD
Tech 53.0
Fund 54.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ENTX +24.72%
MTNB -1.01%
Spread: +25.73 pp (ENTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENTX Revenue | MTNB Revenue | ENTX Op. Margin | MTNB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -12230.9% | MTNB |
| FY2019 | N/A | $0M | N/A | -21067.4% | MTNB |
| FY2020 | $0M | $0M | -3059.7% | -15288.4% | ENTX |
| FY2021 | $0M | $0M | -2139.6% | -74954.5% | ENTX |
| FY2022 | $0M | $0M | -9714.2% | -771.3% | MTNB |
| FY2023 | N/A | $0M | N/A | -2168.4% | MTNB |
| FY2024 | $0M | N/A | -5295.6% | N/A | ENTX |
| FY2025 | $0M | N/A | -27450.0% | N/A | ENTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ENTX | MTNB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $571.2M | $902,069 | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | -100.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -20.3% | -147.5% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 73% ($1โ$4) | 22% ($0โ$3) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 0.92ฮฒ ยท 53% Vol | -6.35ฮฒ ยท 138% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 47.5 / 100 (HOLD) | 52.8 / 100 (HOLD) | Higher Composite | MTNB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ENTX vs MTNB Buy Guide
ENTX
CONSOLIDATION
83d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
33rd %ile
IV Regime
Balanced (25thโ60th %ile)
MTNB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ENTX nor MTNB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.